San Diego-dependent Viking Therapeutics marked alone as a serious competitor while in the weight loss drug industry in February after revealing promising data from the mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented being a weekly injection As well as in March the compa

San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor within the weight loss drug market in February right after revealing promising details from a mid-stage demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when offered to be a weekly injection As well as i